Daily Medication Pearl: Valbenazine (Ingrezza)

Article

Valbenazine (Ingrezza) is indicated for the treatment of adults with tardive dyskinesia.

Medication Pearl of the Day: Valbenazine (Ingrezza)

Indication: Valbenazine (Ingrezza) is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.

Insight:

  • Dosing:The initial dose is 40 mg once daily. After 1 week, increase the dose to the recommended dose of 80 mg once daily.
  • Dosage forms: Capsules 40 mg.
  • Adverse events: Most common adverse reaction (≥5% and twice the rate of placebo) is somnolence.
  • Mechanism of action: The mechanism of action of valbenazine in the treatment of tardive dyskinesia is unknown but is thought to be mediated through the reversible inhibition of VMAT2, a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.
  • Manufacturer: Neurocrine Biosciences

Source: INGREZZATM (valbenazine) capsules Label (fda.gov)

Related Videos
Pride flags during pride event -- Image credit: ink drop | stock.adobe.com
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
Young woman using smart phone,Social media concept. - Image credit: Urupong | stock.adobe.com
selling mental health medication to man at pharmacy | Image Credit: Syda Productions - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.